EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
The EAHP EU Monitor is a weekly round up of news relevant to hospital pharmacy in Europe.
You can subscribe to the EAHP EU Monitor here.
Speaking in advance of World Tuberculosis (TB) day (24 March), Dr Roberto Frontini, President of the European Association of Hospital Pharmacists (EAHP), has warned European healthcare system managers and policy makers to take proactive measures now to meet the growing problem of Multi-Drug Resistant TB and the emergence of Extensively-Drug Resistant TB.
Dr Frontini highlighted 5 measures currently available to policy-makers to make a meaningful contribution to meeting the TB challenge…
More information here
Two of the European Parliament’s Committees scrutinising Commission proposals for improving clinical trial regulation voted on draft opinions this week, with transparency of result reporting a prime consideration. 
Romanian ALDE MEP Dr Christian Silviu Busoi is the Internal Market Committee (IMCO)’s lead rapporteur on the subject file and delivered a draft opinion that focused on issues such as ensuring due and proper ethical assessment of a trial and the categories of information to be included in the summary of a trial’s results. The Committee supported most of the proposed amendments.
The second Committee to vote on its opinion was the Industry and Research Committee (ITRE). The lead rapporteur rMichèle Rivasi, a Green MEP from France, was unsuccessful in passing all her suggested amendments in respect of increasing transparency for and access to data gained from clinical trials involving humans. Although the Committee did not provide formal reasoning as to why her suggested amendments on transparency were rejected, critics of widespread access to clinical trials data have said that demanding too much information from researchers can overburden them unnecessarily. Critics also suggest such access could also create data protection problems, intellectual property conflicts and could harm competition between companies.
The lead Committee in the Parliament responsible for the scrutiny of the Commission proposals on clinical trial regulation is the Environment and Health Committee (ENVI), with the process being led by Glenis Wilmott (UK, PSE). The ENVI Committee will consider the opinion reports of the ITRE and IMCO Committees in the development of its final report.
EAHP is working in collaboration with other health professional, patient and research organisations to scrutinize developments on this subject file and make suggestions for improvement where appropriate.
Recent Willmott and Busoi opinions reports and amendments available in European languages here.
Summary of ITRE proceedings here.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a number of positive recommendations for new Marketing Authorisations. It also recommended restricted use of Otsuka's Pletal (cilostazol) in the treatment of intermittent claudication.
At its March 2013 meeting the CHMP announced a positive opinion in respect of Gilead Sciences’ Marketing Authorisation Application (MAA) for the once-daily, single tablet regimen Stribild® for the treatment of HIV-1 infection in adult patients who are antiretroviral-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.
A positive opinion was also given for Biogen's Tecfidera, or BG-12, and Sanofi's Aubagio for multiple sclerosis (MS). Both are pills, rather than injections.
The Committee also granted a Positive Opinion to Baxter for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. The product is a combination of human normal immunoglobulin (IGSC, 10%) and recombinant human hyaluronidase, which facilitates the dispersion and absorption of the IGSC.
The CHMP also recommended restricting use of Otsuka's Pletal (cilostazol) in the treatment of intermittent claudication. The regulator said a review, which was requested by the Spanish Agency for Medicines and Health Products (AEMPS), indicates that "the modest benefits of these medicines…are only greater than their risks" in a limited number of patients. The CHMP noted that side effects associated with the drug, which is also sold as Ekistol, include those affecting the heart and serious bleeding. As such, the regulator said that Pletal should only be used in patients whose symptoms had not improved despite lifestyle changes. In addition, the medicine should not be used in patients who have suffered severe tachyarrhythmia, or recent unstable angina, heart attack or bypass surgery, or who take two or more antiplatelet or anticoagulant drugs.
More information here.
(1).gif)
EJHP: Quality Risk Management in Clinical PharmacyThe online first edition of the European Journal of Hospital Pharmacy has this week published an interesting research article on quality risk management processes for the clinical pharmacy field.
The article considers:
– the purpose of risk control
– the use of risk analysis to implement suitable measures for risk reduction
– the application of guidelines from the International Conference on Harmonisation Quality Risk Management
Moreover, the article provides a useful overview of the role of the clinical pharmacist in risk management, medication safety and the prevention of errors.
Full article here.
